F-star Biotechnologische Forschungs- Und Entwicklungsges.m.b.h

Other

F-star Therapeutics, Inc.

Florian Ruker

Gottfried Himmler

Gordana Wozniak-Knopp

Thomas Muster

Hermann W Katinger

Gerda Redl

Franz J Steindl

Alexandra Trkola

Martin Purtscher

Georg Maiwald

Geert Mudde

Daniel C Carter

Joseph X Ho

The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of the immunoglobulin determining binding to an epitope of the cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to the epitope, its use and methods for producing it.

Multivalent immunoglobulins

Libraries of immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.

Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

The present application relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

Display of binding agents

A method for engineering an immunoglobulin having a variable domain and at least one modification in at least two structural loops of the immunoglobulin and determining the binding of the immunoglobulin to an epitope of an antigen, where the unmodified immunoglobulin does not significantly bind to said epitope, comprising the steps of providing a nucleic acid encoding an immunoglobulin having at least two structural loops, modifying at least one nucleotide residue of each of the structural loops, transferring the modified nucleic acid in an expression system, expressing the modified immunoglobulin, contacting the expressed modified immunoglobulin with an epitope, and determining whether the modified immunoglobulin binds to the epitope.

Method for engineering immunoglobulins

A method of engineering immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind.

The present invention relates to a method of preparing a genetic package displaying oligomers of modular antibody domains binding to a target and to a scaffold ligand as well as to vectors and libraries of genetic packages produced thereby. The invention further relates to methods of selecting suitable linker sequences for use in such oligomer display.

A recombinant serum albumin is provided which has been modified in the heme binding region so as to have the ability when bound to heme to be capable of reversibly binding oxygen. The modifications are directed to replacing at least one of several hydrophobic binding residues in the natural heme binding region with a hydrophilic residue such as histidine, or by inserting a histidine into these regions, and the resulting recombinant hemealbumin complex, or hemalbumin, is able to reversibly transport oxygen in a manner not possible using natural albumin. The resulting oxygen-transporting recombinant hemalbumin compositions of the invention can be utilized as safe and effective blood replacement compositions, or in other applications such as preservation of organs for transplantation which presently use serum albumin, and these compositions will be advantageous because they can function both as blood volume expanders and as oxygen transport systems at the same time.

Oxygen-transporting albumin-based blood replacement composition and

This invention concerns peptides binding to antibodies which show neutralizing activity against different strains and clinical isolates of HIV-1 and which inhibit the fusion of cells infected with HIV-1. These peptides are combined with an adjuvant, as recombinant fusion proteins, chemically coupled to carrier molecules, as recombinant chimeric viruses or as recombinant antibodies.

Peptides that induce antibodies which neutralize genetically divergent

The present invention relates to fusion peptides wherein at least one peptide consisting of an amino acid sequence selected from the group consisting of SEQ ID NO: 1 through SEQ ID NO: 25 is bound to an adjuvant being a protein molecule by fusion of the respective nucleotide sequences and subsequent expression of the fusion genes in a biological expression system.

This invention refers to peptides binding to antibodies that show neutralizing activity against different strains and clinical isolates of HIV-1 and that inhibit the fusion of cells caused by HIV-1. These peptides are applied with an adjuvant, as recombinant fusion proteins, chemically coupled to carrier molecules, as recombinant chimeric viruses or as recombinant antibodies.

Growing community of inventors

Vienna, Austria

Florian Ruker